Rose became acquainted with Patient Worthy after her husband was diagnosed with Acute Myeloid Leukemia (AML) six years ago. During this period of partial remission, Rose researched investigational drugs to be prepared in the event of a relapse. Her husband died February 12, 2021 with a rare and unexplained occurrence of liver cancer possibly unrelated to AML.

    Neuroscientists Are Focusing on Synthetic Pharmaceuticals to Restore Cognitive Function in Alzheimer’s Disease
    source: pixabay.com

    Neuroscientists Are Focusing on Synthetic Pharmaceuticals to Restore Cognitive Function in Alzheimer’s Disease

    Improving cognition and identifying abnormal molecular pathways in Alzheimer’s disease has been challenging. Current studies of Alzheimer’s disease have focused on reducing such occurrences as amyloid plaque, neuroinflammation, and neurofibrillary…

    Continue Reading Neuroscientists Are Focusing on Synthetic Pharmaceuticals to Restore Cognitive Function in Alzheimer’s Disease

    Sabatolimab Can Be Added Safely to Hypomethylating Agents in the Treatment of MDS and AML

    Dr. Andrew Brunner, an oncologist at Massachusetts Cancer Center was recently interviewed by Targeted Oncology. The discussion centered around a phase 1b clinical trial (NCT03066648) investigating sabatolimab together with hypomethylating…

    Continue Reading Sabatolimab Can Be Added Safely to Hypomethylating Agents in the Treatment of MDS and AML
    A Common Parasite With An Uncommon Name: Toxoplasma gondii is Associated with Brain Cancer
    source: pixabay.com

    A Common Parasite With An Uncommon Name: Toxoplasma gondii is Associated with Brain Cancer

      Toxoplasmosis is transmitted by Toxoplasma gondii, the protozoan parasite which is known to be among the most common parasites worldwide. The infection occurs from contaminated meat, cat feces that…

    Continue Reading A Common Parasite With An Uncommon Name: Toxoplasma gondii is Associated with Brain Cancer
    Discovery of Three Molecular Subtypes Brings Us Closer to Unraveling Alzheimer’s Disease
    source: pixabay.com

    Discovery of Three Molecular Subtypes Brings Us Closer to Unraveling Alzheimer’s Disease

      There are many common elements in Alzheimer’s disease (AD), which is the most common type of dementia. It is now evident that there are varied spans of disease progression…

    Continue Reading Discovery of Three Molecular Subtypes Brings Us Closer to Unraveling Alzheimer’s Disease

    A New Method of Delivering Drugs Through the Blood-Brain Barrier To Treat Neurological Disorders

    Over the past decade, scientists have made many life-saving advances in all areas of medicine. They have created molecular agents to target neurodegenerative diseases. But they were stopped right there…

    Continue Reading A New Method of Delivering Drugs Through the Blood-Brain Barrier To Treat Neurological Disorders

    New Finding: Overactive Mitochondria Are Responsible for Twenty Percent of Glioblastoma Brain Cancers

    Neuroscience News recently carried an article heralding reports of researchers' finding that upwards of twenty percent of lethal glioblastoma brain cancers may be treatable by newly developed drugs. Currently, the…

    Continue Reading New Finding: Overactive Mitochondria Are Responsible for Twenty Percent of Glioblastoma Brain Cancers
    Experimental Treatment Could be Useful in Numerous Rare and Deadly Cancers
    source: pixabay.com

    Experimental Treatment Could be Useful in Numerous Rare and Deadly Cancers

    While novel treatments have been rapidly emerging onto the drug scene, new treatment options for pancreatic cancer have fallen behind. But now, according to OncLive’s interview with Dr. P.A. Philip,…

    Continue Reading Experimental Treatment Could be Useful in Numerous Rare and Deadly Cancers
    Patients Who Received CRISPR Gene Editing for Beta Thalassemia and Sickle Cell Disease Remain Pain Free
    source: pixabay.com

    Patients Who Received CRISPR Gene Editing for Beta Thalassemia and Sickle Cell Disease Remain Pain Free

      The initial CRISPR treatment for sickle cell disease was administered to Victoria Gray in July 2019. Victoria, a resident of Forest, Mississippi, was born with sickle cell and has…

    Continue Reading Patients Who Received CRISPR Gene Editing for Beta Thalassemia and Sickle Cell Disease Remain Pain Free
    Infusion of Yescarta Resulted in 44 Percent 4-year Overall Survival Rate in Large B-cell Lymphoma
    source: pixabay.com

    Infusion of Yescarta Resulted in 44 Percent 4-year Overall Survival Rate in Large B-cell Lymphoma

      A recent announcement by Gilead Company citing data from Kite Pharma, one of its premier companies, set out remarkable results from Kite’s Zuma-1 clinical trial. The findings confirmed that…

    Continue Reading Infusion of Yescarta Resulted in 44 Percent 4-year Overall Survival Rate in Large B-cell Lymphoma